LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

LLY

1,027.44

+2.13%↑

JNJ

211.44

+0.72%↑

ABBV

223.45

-0.16%↓

UNH

341.39

+1.44%↑

AZN

89.79

-0.45%↓

Kodu・Aktsiate loetelu・Mirati Therapeutics Inc

Mirati Therapeutics Inc

Suletud

SektorTervishoid

Osta Müü

Ülevaade

Aktsiahinna muutus

24h

Praegune

Min

Max

Soovitused
By TipRanks
Soovitused	Neutraalne
12 kuu keskmine prognoos	-0.05% downside

Uudiste sentiment

By Acuity

14%

86%

11 / 374 Pingereas Healthcare

Mirati Therapeutics Inc Graafik

Mineviku tootlus ei ole usaldusväärne näitaja tulevaste tulemuste kohta.

Seotud uudised

12. dets 2025, 16:42 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725 Million Deal for Liquid Nails From PE Firm -- 2nd Update

12. dets 2025, 23:49 UTC

Omandamised, ülevõtmised, äriostud

Intel in Talks to Acquire SambaNova in Deal Valued at $1.6B, Bloomberg Reports, Citing Sources

12. dets 2025, 22:52 UTC

Market Talk

Nike Expected to Show Further Momentum in 2Q Results -- Market Talk

12. dets 2025, 22:32 UTC

Tulu

These Stocks Moved the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 21:50 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 20:45 UTC

Tulu

The Best Dividend ETF for Right Now -- and 2026 -- Barrons.com

12. dets 2025, 20:41 UTC

Market Talk

Oil Ends Week Lower As Market Frets About Oversupply -- Market Talk

12. dets 2025, 20:20 UTC

Market Talk

U.S. Natural Gas Futures Post Hefty Weekly Loss -- Market Talk

12. dets 2025, 19:23 UTC

Tulu

Charles Schwab Is Opening New Accounts and Hauling in New Assets Amid Buoyant Stock Market -- Barrons.com

12. dets 2025, 18:35 UTC

Omandamised, ülevõtmised, äriostud

PNC Financial Expects to Close FirstBank Deal On or About Jan. 5, Subject to Satisfaction of Customary Closing Conditions

12. dets 2025, 18:33 UTC

Omandamised, ülevõtmised, äriostud

PNC Receives Regulatory Approvals For Acquisition Of FirstBank >PNC

12. dets 2025, 18:31 UTC

Market Talk

U.S. Oil Rig Count Edges Up by 1 to 414 -- Market Talk

12. dets 2025, 17:49 UTC

Tulu

Tariffs Mean Costco Has Fewer Product Types This Holiday. But It Has Plenty of Pies. -- WSJ

12. dets 2025, 17:34 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing Subject to Customary Regulatory Approvals, Other Closing Conditions

12. dets 2025, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Orange: Closing of the Transaction Is Expected in the First Half of 2026

12. dets 2025, 17:33 UTC

Omandamised, ülevõtmised, äriostud

Orange: Agreement Confirms the Non-Binding Agreement That Was Previously Announced Oct. 31

12. dets 2025, 17:32 UTC

Omandamised, ülevõtmised, äriostud

Orange: MasOrange Is Spain's Leading Operator in Terms of Customer Base

12. dets 2025, 17:31 UTC

Omandamised, ülevõtmised, äriostud

Orange to Buy the Stake for EU4.25B in Cash

12. dets 2025, 17:24 UTC

Market Talk

Argentina Predicts Record Wheat Crop -- Market Talk

12. dets 2025, 17:20 UTC

Market Talk

Tulu

Tech, Media & Telecom Roundup: Market Talk

12. dets 2025, 17:20 UTC

Market Talk

Basic Materials Roundup: Market Talk

12. dets 2025, 17:18 UTC

Market Talk

Tulu

Broadcom, Oracle Investor Reactions Show High Bar for AI Cos. -- Market Talk

12. dets 2025, 17:09 UTC

Market Talk

Broadcom Investors Were Primed to Sell Shares -- Market Talk

12. dets 2025, 17:09 UTC

Market Talk

Global Equities Roundup: Market Talk

12. dets 2025, 16:47 UTC

Market Talk

Broadcom's Margins Expected to Narrow Due to AI Revenue -- Market Talk

12. dets 2025, 16:39 UTC

Market Talk

Supply Limits, Geopolitical Risk to Support Crude in 2026 -- Market Talk

12. dets 2025, 16:27 UTC

Omandamised, ülevõtmised, äriostud

FTC Sues to Block Henkel's $725M Deal for Liquid Nails From PE Firm -- 2nd Update

12. dets 2025, 16:15 UTC

Tulu

At Costco, Lots of Pie but No Special Dividend. Why the Street Didn't Like the Earnings. -- Barrons.com

12. dets 2025, 15:35 UTC

Tulu

These Stocks Are Moving the Most Today: Broadcom, Oracle, Fermi, Tilray, Lululemon, Costco, Netskope, and More -- Barrons.com

12. dets 2025, 14:46 UTC

Market Talk

Global Forex and Fixed Income Roundup: Market Talk

Võrdlus sarnastega

Hinnamuutus

Mirati Therapeutics Inc Prognoos

Hinnasiht

By TipRanks

-0.05% langus

12 kuu keskmine prognoos

Keskmine 58.67 USD -0.05%

Kõrge 59 USD

Madal 58 USD

Põhineb 5 Wall Streeti analüütiku instrumendi Mirati Therapeutics Inc 12 kuu hinnasihil - viimase 3 kuu andmed.

Hinnangu Konsensus

By TipRanks

Neutraalne

5 ratings

Osta

Hoia

Müü

Põhineb 5 analüütiku instrumendi Mirati Therapeutics Inc aktsia reitingul - viimase 3 kuu andmed.

Sentiment

By Acuity

11 / 374 Pingereas Tervishoid

Finantsandmed

Müügi- ja halduskulud

Tegevuskulud

Maksueelne kasum

Müük

Müügikulu

Brutokasum müügist

EBITDA

Ärikasum

Ettevõttest Mirati Therapeutics Inc

Mirati Therapeutics, Inc. is a clinical-stage oncology company. It is focused on developing therapeutics to address the genetic and immunological promoters of cancer. Its clinical programs consist of product candidates, including Adagrasib (MRTX849), MRTX1133, and Sitravatinib. MRTX849 is an oral small-molecule therapy designed to shrink difficult-to-treat cancers harboring the KRAS G12C mutation. MRTX1133 is a small molecule-inhibitor of the KRASG12D mutation, designed to treat patients with unmet need. Sitravatinib is a spectrum-selective receptor tyrosine kinase (RTK) inhibitor that can stimulate the body’s immune response to fight cancer. MRTX849 is in Phase III and Phase I/II clinical trials and MRTX1133 is in preclinical development. Sitravatinib is in a Phase III clinical trial, and Phase I/II clinical trials. It also has additional preclinical discovery programs, which includes first-in-class and best-in-class product candidates designed to address mutations and tumors.